Maze Therapeutics (NASDAQ:MAZE) Raised to "Strong-Buy" at TD Cowen

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) was upgraded by research analysts at TD Cowen to a "strong-buy" rating in a report issued on Tuesday,Zacks.com reports.

Several other brokerages also recently issued reports on MAZE. Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price target on the stock. Leerink Partners assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective for the company. Finally, Guggenheim started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set a "buy" rating and a $19.00 price target on the stock. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $25.67.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE traded down $0.49 during trading hours on Tuesday, hitting $12.23. 141,658 shares of the company's stock were exchanged, compared to its average volume of 324,193. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.

Remove Ads

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.